MarketBeat
18 Nov 2026, 05:13 UTC · 4h ago
MannKind Sees Profitability Next Year as FUROSCIX Conversion Beats Expectations
Impact · against what's priced in
MannKind's outlook improves based on accelerated adoption of the FUROSCIX ReadyFlow format and a clear path toward profitability by 2027. The ability to potentially pull forward the MNKD-201 trial timeline via U.S. site additions provides additional upside, while the United Therapeutics partnership remains a stable long-term foundation.
- MNKD+0.70
No priced-in read yet





